Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cyclophosphamide + Doxorubicin + Parsaclisib + Pegfilgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab + Vincristine Sulfate|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 16||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Doxorubicin||Adriamycin||Adria|ADR|Doxorubicin hydrochloride|Hydroxydaunorubicin||Chemotherapy - Anthracycline 13 TOPO2 inhibitor 5||Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov).|
|Parsaclisib||INCB050465|INCB 50465|INCB-50465|INCB50465|WHO 10589||PIK3CD inhibitor 27||Parsaclisib (INCB050465) inhibits PI3K-delta, blocking activation of AKT signaling pathway and leading to apoptosis of PIK3CD expressing tumor cells (PMID: 31749910).|
|Pegfilgrastim||Neulasta||GCSF-SD01||Neulasta (Pegfilgrastim) is a pegylated version of filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF), which enhances proliferation, differentiation, and activity of neutrophils (NCI Drug Dictionary).|
|Polatuzumab vedotin-piiq||Polivy||ADC DCDS4501A|DCDS4501A|FCU 2711|RG7596|Ro 5541077-000|Polatuzumab Vedotin||Polivy (polatuzumab vedotin-piiq) is a monoclonal antibody against B-cell antigen receptor complex-associated protein beta chain (CD79B) linked to monomethyl auristatin E (MMAE), which may deliver the cytotoxic MMAE to tumor cells over expressing CD79b (PMID: 26194424). Polivy (polatuzumab vedotin-piiq) is FDA-approved for use in combination with Treanda (bendamustine) and Rituxan (rituximab) in patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more prior therapies, and in combination with R-CHP in patients with untreated diffuse large B-cell lymphoma, not otherwise specified (NOS), or high-grade B-cell lymphoma with an IPI score of 2 or greater (FDA.gov).|
|Prednisone||Adasone||Dehydrocortisone||Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary).|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 20||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia, and in combination with chemotherapy in pediatric patients (6 month to 18 years of age) with treatment-naive, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL) (FDA.gov).|
|Vincristine Sulfate||Oncovin||22-Oxovincaleukoblastine|vincristine||Oncovin (vincristine) binds microtubules and prevents mitotic spindle formation, resulting in cell-cycle arrest (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04323956||Phase I||Cyclophosphamide + Doxorubicin + Parsaclisib + Pegfilgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Parsaclisib + Pegfilgrastim + Prednisone + Rituximab + Vincristine Sulfate||Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma||Active, not recruiting||USA||0|